MedPath

CHINA MEDICAL UNIVERSITY

🇹🇼Taiwan
Ownership
Private
Employees
-
Market Cap
-
Website
http://english.cmu.edu.tw

Clinical Trials

85

Active:1
Completed:30

Trial Phases

5 Phases

Phase 1:9
Phase 2:21
Phase 3:4
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (74 trials with phase data)• Click on a phase to view related trials

Phase 2
21 (28.4%)
Phase 4
21 (28.4%)
Not Applicable
19 (25.7%)
Phase 1
9 (12.2%)
Phase 3
4 (5.4%)

A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status

Phase 2
Recruiting
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: denosumab combined anti-PD-1 inhibitor with chemotherapy
First Posted Date
2025-06-24
Last Posted Date
2025-06-24
Lead Sponsor
China Medical University, China
Target Recruit Count
40
Registration Number
NCT07034391
Locations
🇨🇳

The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China

The Effect of Situation Puzzle Games on Nursing Students' Death Anxiety and Meaning in Life

Not Applicable
Recruiting
Conditions
Death Anxiety
First Posted Date
2025-05-28
Last Posted Date
2025-05-28
Lead Sponsor
China Medical University, China
Target Recruit Count
70
Registration Number
NCT06991621
Locations
🇨🇳

School of Nursing, China Medical University, Shenyang, Liaoning, China

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Phase 4
Not yet recruiting
Conditions
Small Cell Lung Cancer
Interventions
First Posted Date
2025-04-30
Last Posted Date
2025-04-30
Lead Sponsor
China Medical University, China
Target Recruit Count
31
Registration Number
NCT06951841
Locations
🇨🇳

The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Phase 2
Not yet recruiting
Conditions
Gastric Cancer
HER2 + Gastric Cancer
PD-L1 Positive
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
Interventions
First Posted Date
2025-03-18
Last Posted Date
2025-03-18
Lead Sponsor
China Medical University, China
Target Recruit Count
140
Registration Number
NCT06881017

Effects of Different Occlusion Angles of Disposable Tracheal Blocker on Right One-lung Ventilation

Not Applicable
Recruiting
Conditions
The Direction of Blocker Placement
First Posted Date
2024-09-13
Last Posted Date
2024-09-16
Lead Sponsor
China Medical University, China
Target Recruit Count
96
Registration Number
NCT06595043
Locations
🇨🇳

Wenfei Tan, Shenyang, China

🇰🇷

Konkuk University School of Medicine, Seoul, Korea, Republic of

🇷🇸

the University Clinical Center of Serbia, Belgrade, Serbia

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 17
  • Next

News

China Medical University Achieves Milestone with CAR001 Cell Therapy for Solid Tumors

China Medical University (CMU) and Healthcare System secured 17 awards at the Taiwan National Innovation Awards, recognizing breakthroughs in biotechnology and smart healthcare.

Sacituzumab Tirumotecan Demonstrates Antitumor Activity in Advanced Endometrial and Ovarian Cancers

Sacituzumab tirumotecan (sac-TMT) monotherapy shows promising antitumor activity in patients with previously treated advanced endometrial cancer, with an objective response rate (ORR) of 34.1%.

© Copyright 2025. All Rights Reserved by MedPath